生命科学资讯
生物技术与制药领域的最新动态
Pfizer dips on new data for obesity drug acquired in $10B deal
辉瑞每月投入100亿美元押注GLP-1药物，二期b阶段试验显示减肥效果具竞争力。
Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b
辉瑞第四季度财报中因抗癌药物计提44亿美元减值准备
Pfizer takes $4.4B charge related to cancer drug in fourth-quarter earnings
辉瑞源自Metsera的月度GLP-1药物在六个月内减重10.5%
Pfizer’s Metsera-originated monthly GLP-1 cuts weight by 10.5% at six months
辉瑞CEO将美国疫苗困境归咎于小肯尼迪的“反科学”立场：《华尔街日报》报道
Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
辉瑞签署5.3亿美元协议，将在两个项目中应用诺瓦瓦克斯疫苗佐剂技术。
Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs
辉瑞退出葛兰素史克ViiV，盐野义制药持股翻倍。
Pfizer to depart GSK's ViiV as Shionogi doubles its stake
JPM26：美国生物科技的“斯普特尼克时刻”，辉瑞的减肥药雄心与百时美施贵宝的关键之年
JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year
应FDA要求，辉瑞协助缓解潜在自闭症药物短缺问题。
At FDA's request, Pfizer helps ease shortage of potential autism drug
Madrigal斥资5000万美元收购辉瑞MASH药物，着眼与Rezdiffra联合疗法潜力。
Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential
法国生物技术公司Enodia获辉瑞2070万欧元资助，专注蛋白质降解剂研发。
French biotech Enodia gets €20.7M aided by Pfizer for protein degrader work
更新：辉瑞披露Hympavzi血友病试验中患者死亡事件
Updated: Pfizer discloses patient death in Hympavzi hemophilia trial
诺和申请CagriSema批准；默克与辉瑞试验告捷
Novo files for CagriSema approval; Merck and Pfizer’s trial win
辉瑞RNA负责人转投Replicate公司
Chutes & Ladders—Pfizer RNA leader runs to Replicate
辉瑞押注肥胖症药物，以应对重大专利悬崖。
Pfizer bets big on obesity to offset major patent cliff
FDA“主动”授予强生优惠券；辉瑞发布2026年预测。
FDA ‘proactively’ hands J&J a voucher; Pfizer issues 2026 forecasts
辉瑞与赛诺菲年末分别签署自身免疫性疾病合作协议。
Pfizer, Sanofi pull out checkbooks for separate year-end autoimmune pacts
辉瑞以20亿美元收购药明康德，增强肥胖症药物研发实力。
Pfizer adds heft to obesity pipeline in $2B Yaopharma deal
辉瑞再度押注肥胖症治疗，斥资1.5亿美元预付款引进复星医药GLP-1药物。
Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug